AlphaMadera
AbbVie Inc. (ABBV)
$289.21
-0.03 (-0.01%)Delayed quote.
Price history
Daily close- Start
- $211.96
- Latest close
- $288.94
- Period change
- +36.32%
- Period low
- $197.38
- Period high
- $294.89
Key metrics
- Market cap
- $510.52B
- Volume
- 275.8K
- Average volume
- 5.71M
- 52-week range
- $190.75 – $298.74
- Beta
- 0.28
- Last dividend
- $6.92
- EPS (TTM)
- $5.83
- P/E ratio
- 49.61
- Revenue (TTM)
- $66.01B
- Net income (TTM)
- $10.35B
- Total assets
- $135.13B
- Total debt
- $70.82B
- Cash and equivalents
- $6.57B
Key financials (trailing twelve months).
Company profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- CEO
- Robert A. Michael
- Employees
- 57,000
- Headquarters
- North Chicago, IL, US
- IPO date
- 2013-01-02
- Website
- https://www.abbvie.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B |
| Gross profit | $42.96B | $39.43B | $33.90B |
| Operating income | $20.09B | $9.14B | $12.76B |
| EBITDA | $17.63B | $14.91B | $17.17B |
| Net income | $4.23B | $4.28B | $4.86B |
| Diluted EPS | $2.37 | $2.39 | $2.72 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $5.23B | $5.52B | $12.81B |
| Total assets | $133.96B | $135.16B | $134.71B |
| Total liabilities | $137.19B | $131.80B | $124.31B |
| Total debt | $69.07B | $67.84B | $60.12B |
| Shareholders’ equity | -$3.27B | $3.33B | $10.36B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B |
| Capital expenditure | -$1.21B | -$974.00M | -$777.00M |
| Free cash flow | $17.82B | $17.83B | $22.06B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.40B | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B |
| Gross profit | $14.79B | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B |
| Operating income | $6.48B | $6.43B | $4.73B | $5.81B | $1.90B | $4.89B |
| EBITDA | $6.48B | $8.61B | $3.69B | $5.37B | $3.52B | $4.34B |
| Net income | $4.22B | $3.61B | $699.00M | $1.82B | $186.00M | $938.00M |
| Diluted EPS | $2.38 | $2.04 | $0.39 | $1.02 | $0.10 | $0.53 |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B |
| Total assets | $135.13B | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B |
| Total liabilities | $141.00B | $143.07B | $137.19B | $136.50B | $137.32B | $134.70B |
| Total debt | $70.82B | $72.86B | $68.87B | $68.74B | $70.48B | $69.89B |
| Shareholders’ equity | -$5.93B | -$6.66B | -$3.27B | -$2.64B | -$183.00M | $1.42B |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | $1.64B |
| Capital expenditure | -$322.00M | -$265.00M | -$329.00M | -$381.00M | -$269.00M | -$235.00M |
| Free cash flow | $3.11B | $3.56B | $4.89B | $6.64B | $4.88B | $1.40B |